gene-silencing
-
HDSA’s Q&A on the latest huntingtin-lowering update from Ionis and Roche
Our friends at @hdsa have produced this really good Q&A document about the latest huntingtin-lowering news.
By Dr Leora Fox -
Huntington's disease therapeutics conference 2018 – day 3
Updates from day 3 of the Huntington’s Disease Therapeutics Conference: huntingtin protein – and lowering it
-
An early role for the Huntington's disease gene – but don't believe all the headlines
A surprising new paper sheds light on the role of the HD gene early in development. Should we worry?
-
Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
-
New roles for huntingtin: removing a healthy protein to understand its function
Completely removing normal huntingtin in adults may disrupt healthy brain function, a recent study suggests.
By Dr Leora Fox -
Precision huntingtin-lowering drug trials target the mutant protein
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
-
Update confirms Huntington's disease 'gene silencing' trial on track
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
-
Huntington's Disease Therapeutics Conference 2017 – Day 2
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 2
-
Important advances in next generation genome editing tools for Huntington's Disease
Work with genome editing techniques (zinc fingers and CRISPR) brings these tools closer to use in HD clinical trials
-
Planting trees together: The 2016 Huntington's Disease Society of America Convention
HDBuzz summarizes the science from an unusually large and energized @HDSA convention in Baltimore